1,143 karma · joined November 22, 2008
A pacer is different than a brain stimulator. And pacers generally try to restart themselves if they can. Brain stimulators, because of the sensitivity of where you’re stimulating (a few cm, literally, away from regions that control breathing, heart rate, etc), the least risky option is a shut down.
As part of the design process for every FDA-regulated product, you are obliged to perform a risk analysis to judge the severity and probability of risks to a patient using your product.
One of the risks was “Exposed to a strong current that could destroy/disable the onboard electronics”. The design mitigation was a fail safe shutdown.
Homelessness however is more a multi-headed beast, and Japanese culture likely plays as much into a lack of people on the street as does housing availability.
They were stopped because DoD regulations state that medical products used by the military have to be cleared/approved by FDA (or in the process of a clinical trial). And Theranos was not on FDA’s “good” list at the time, having only sent one product through the clearance process out of the dozens they were selling.
Now one could argue that biocomp testing, which is done on animal models for the most part, is insufficient for any implanted device. That's a fair argument and one worth having. But the linked op-ed is a polemic.
And, yeah, FDA recently increased the range of condom sizes they would accept, thus enabling the kind of thing you’re proposing.
Thanks! Sounds like you’re pretty well-versed in this, if there’s some way you can help you with a future product please reach out!
De novo’s definitely, abbreviated 510(k)’s as well (that’s more of a requirements -> standard conformance challenge which a system like ours is particularly suited to demonstrate), but to your point they’re not that common.
> In my eyes it's really a question of how long FDA will be expecting traditional submissions while they roll out a model geared more around approval of companies vs products.
Yes but in a certain sense for many digital health companies this is already true, because they’re 510(k) exempt and FDA’s oversight occurs retroactively via QMS auditing.
The near term challenge for digital health, until precert comes online, is that there are a limited number of software experts at FDA. To the Agency’s credit, they have recognized this and are trying to remedy it. But the big problem we see with software submissions is that things get overlooked, and in such a way that speaks to an overworked reviewers. This of course leads to delays, which is why it’s very important for software submissions to be buttoned up. This is one the things we’re tryijg to make happen with our QMS, which generates more reports that clearly map from requirement->code->test.
1) Compliance is an ongoing activity regardless of how many new products you release. Think something like HIPAA, but more pervasive. So there’s an ongoing need that is ordinarily fulfilled by people - everything from a consultant for a garage startup to 1,000s of FTEs for a Fortune 500 company. This creates an ongoing, sticky customer relationship for anyone who can deliver significant value.
2) Our product and approach is valuable to more than just startups and enterprise life science companies routinely spend $10M+/yr on software systems.
Registration and listing: harder to automate because information systems on FDA’s side aren’t quite there yet. For GUDID, yes
CAPA, labeling, submissions: yes
Alternative submission pathways: what do you mean by this precisely?
Pre-cert: I think the premise is correct, in that the current quality system regulations aren’t well suited to modern SW development practice. But the devil will be in the details. Regardless it won’t affect us significantly because whatever gets released will have to have a phase-in for existing process that we’ll be able to adapt to.
1) https://www.atomwise.com 2) https://www.recursionpharma.com
Reno? Easy. No ecosystem, aside from specialized things (Gigafactory etc).
I would LOVE to start an accelerator type thing just over the border of SLT, CA. But I would expect everyone would leave at the end of the it for a larger metro.
This is a correct and useful analogy. Nonetheless, biologists are excited about CRISPR because, to continue your analogy, we were previously working with spears. And now we have bullets. Still don't know where to quite fire them yet. But it's a nontrivial advance.
Any drug submission that supports shelf life via ALT data will be expected to also say "and we're doing real time testing to support this", and FDA will expect the follow up real-time data.
On a brand new MBP, though. Maybe that has an effect.
Vegas relies on the Colorado River, which is very overtaxed for what it supports now (Vegas + Phoenix)
Larry and Sergey could fix MV's intransigence very fast. We need to call on tech leadership to take a stand here. It's in their best interest.
+1 to all the suggestions about calling your city council, your assemblymember, your state senator, etc